Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
NanoViricides began enrolling and dosing patients in a Phase IIA/IIB trial of its oral NV-387 gummies for Ebola in the DRC, with dosing started on or about Sept. 23, 2026.Material DetailsContext by AI AnalystThis is an early-to-mid stage clinical step advancing NV-387 from COVID work into Ebola dur…
The company said it began enrolling and dosing patients in Democratic Republic of Congo study of NV-387 oral gummies for Bundibugyo ebolavirus. It said the initial dose run-in is intended to set a tolerable dosing approach before later randomized efficacy testing.